参芪扶正注射液配合化疗治疗胃癌临床疗效观察

Clinical Study on Effect of Shenqi Fuzheng Injection Combined with Chemotherapy in Treating Gastric Cancer

目的：验证参芪扶正注射液的临床疗效。方法：随机分为３组比较疗效。化疗加参芪组（治疗组，化疗加静脉滴注参芪扶正注射液）６２例，化疗对照组（化疗组，单用化疗）３７例，单纯参芪组（参芪组，单用参芪扶正注射液）２１例。观察疗效，并观察自然杀伤（ＮＫ）细胞、巨噬细胞及Ｔ细胞亚群等治疗前后变化。结果：治疗组对胃癌癌灶的缓解率为１６１％，稳定率为８７１％，化疗组为１３５％和６４９％，组间比较稳定以上率有显著性差异。对气虚证及生存质量的改善疗效也很明显，治疗组分别为７５８％和４３５％，参芪组是６１９％和５７１％，化疗组为３５１％和２９７％。对骨髓造血功能也有较好的维护作用，治疗组白细胞治疗后低于４×１０９／Ｌ者占４８％，化疗组为２１６％，组间有显著性差异。同时能提高ＮＫ细胞、巨噬细胞、Ｔ淋巴细胞亚群的活性。临床用药安全可靠，无明显不良反应，对心、肝、肾等主要脏器无损伤作用。结论：参芪扶正注射液配合化疗对胃癌癌灶有一定的缓解和稳定作用，对气虚患者，临床疗效显著，用药安全可靠。

Objective: To assess the clinical effect of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating gastric cancer. Methods: One hundred and twenty patients were randomly divided into 3 groups, the combined therapy group (Group A), the chemotherapy group (Group B) and the SQFZI group (Group C) and the effect on remission and stabilization of patients were observed. Results: The remission rate and stabilizing rate of Group A were 16.1% and 87.1%, those of Group B were 13.5% and 64.9%, the difference between the two groups was significant, P<0 05. The symptom and living quality improving rate of Group A were 75.8% and 43.5% respectively, those of Group C were 61.9% and 57.1% and of Group B were 35.1% and 29.7% respectively. SQFZI showed good protective effect on hemopoietic system, 4.8% patients in Group A with WBC count lower than 4×10 9/L, while the percentage reached 21.6% in Group B, the difference between the two groups was significant, P<0 05. Moreover, SQFZI could raise activity of NK cell, macrophage and T lymphocyte subgroups, without any injury on heart, liver and kidney function or other adverse reaction. Conclusions: SQFZI combined with chemotherapy has certain effect of remission and stabilization on gastric cancer, the clinical effect is significant to patients with Qi Deficiency, and is reliable and safe.